Strategies for the Assessment of Protein Aggregates in Pharmaceutical Biotech Product Development

Author： Engelsman John   Garidel Patrick   Smulders Ronald   Koll Hans   Smith Bryan   Bassarab Stefan   Seidl Andreas   Hainzl Otmar   Jiskoot Wim  

Publisher： Springer Publishing Company

ISSN： 0724-8741

Source： Pharmaceutical Research, Vol.28, Iss.4, 2011-04, pp. : 920-933

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmaceutical Pricing and Reimbursement Strategies Over the Whole Product Life Cycle: Practical Considerations

By Lovatt Brian  

International Journal of Pharmaceutical Medicine, Vol. 18, Iss. 6, 2004-01 ,pp. : 343-347

Adis International

Access to resources Recommend Favorite

Pharmaceutical Strategies for Activating Sirtuins

By  

Current Pharmaceutical Design, Vol. 15, Iss. 1, 2009-01 ,pp. : 45-56

Bentham Science Publishers

Access to resources Recommend Favorite

A Review of: “Generic Drug Product Development – Solid Oral Dosage Forms, Drugs and the Pharmaceutical Sciences # 143”

By Brittain Harry  

Pharmaceutical Development and Technology, Vol. 11, Iss. 3, 2006-09 ,pp. : 399-399

Informa Healthcare

Access to resources Recommend Favorite

The Case of Biotech-Derived Product Equivalence: Much Ado About Nothing?

By  

Current Clinical Pharmacology, Vol. 1, Iss. 2, 2006-05 ,pp. : 147-156

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmaceutical Strategies Against Amyloidosis: Old and New Drugs in Targeting a “Protein Misfolding Disease”

By  

Current Medicinal Chemistry, Vol. 11, Iss. 8, 2004-04 ,pp. : 1065-1084

Bentham Science Publishers

Access to resources Recommend Favorite